How to Take Peptides: Injection vs Oral vs Nasal vs Topical

Injection, pill, nasal spray or cream: the route is decided by the molecule, not by preference. Here is why nearly every research peptide ends up in a syringe, which peptides actually have approved non-injected forms, and what the labels on those products say about using and storing them.

Most peptides are taken by subcutaneous injection, because the stomach and gut digest peptides the same way they digest dietary protein: enzymes cut them apart and the intestinal lining blocks the fragments that survive¹. Swallowing works only for a handful of peptides that were re-engineered for it, and even then only a tiny fraction gets through — oral semaglutide's absolute bioavailability is about 0.4–1%², compared with about 100% for a peptide such as bremelanotide injected under the skin⁶. Nasal sprays work for some small, potent peptides, and topical creams act mainly on the skin itself. This guide explains each route and where the evidence stands. For the injection technique itself — reconstitution, drawing a dose, site rotation — see our step-by-step guide to injecting peptides.

The four routes at a glance

Why most peptides are injected: the gut is built to digest them

A peptide is a short chain of amino acids — chemically the same kind of bond your digestive system exists to break. In a 2020 review of oral peptide therapeutics, Daniel Drucker describes the barriers a swallowed peptide faces: stomach acid, proteolytic enzymes in the stomach and small intestine, a mucus layer, and an intestinal lining that lets through little that is large and water-soluble¹. Drug developers have spent decades trying to get around these with permeation enhancers, enzyme inhibitors and cell-penetrating carriers. Oral insulin, calcitonin, parathyroid hormone and vasopressin analogs have all reached clinical trials¹, which tells you how hard the problem is: after all that effort, only a few oral peptide products are on the market.

The numbers make the gap concrete. The Vyleesi label reports that bremelanotide injected under the skin has an absolute bioavailability of about 100%, with peak blood levels about an hour after the dose⁶. The semaglutide tablet label reports an absolute bioavailability of roughly 0.4% to 1% for Rybelsus and 1% to 2% for Ozempic tablets². In other words, more than 98% of the semaglutide in a tablet never reaches the bloodstream, and that is the success story. That is also why the tablets are taken every day in milligram strengths — 3, 7 and 14 mg for Rybelsus².

Oral peptides: the semaglutide exception and what it took

Oral semaglutide works because of formulation, not because semaglutide is naturally absorbable. Each tablet is co-formulated with salcaprozate sodium (SNAC)². In clinical and dog studies published in Science Translational Medicine, absorption took place in the stomach, in a small area right next to the tablet surface, and only when SNAC was present; SNAC buffered the local environment against enzymatic breakdown and briefly increased absorption across the stomach lining³. Because the effect is so local, the tablet has to sit in an almost empty stomach.

That is why the label rules are so specific. Take one tablet once daily on an empty stomach in the morning, with no more than 4 ounces (about 120 mL) of plain water; swallow it whole without splitting, crushing or chewing; and wait at least 30 minutes before eating, drinking or taking other oral medicines². The label's pharmacokinetic section shows why: absorption was higher with 50 mL of water than with 240 mL, and higher with a longer fast after the dose². Rybelsus and Ozempic tablets are not interchangeable milligram for milligram² — the same molecule in two tablet formulations needs two different dose schedules.

Oral semaglutide is approved for type 2 diabetes (Rybelsus and Ozempic tablets)² and, since 22 December 2025, for weight management as the once-daily Wegovy pill at a 25 mg maintenance dose⁴. All three are prescription drugs. For the injectable form and its dose schedule, see our semaglutide reference page.

Nasal sprays: they work for small, potent peptides

The nose is a better entry point than the gut — no stomach acid, fewer digestive enzymes — but it is still far less efficient than an injection. The desmopressin (DDAVP) nasal spray label shows the difference well. When a patient switches from desmopressin injection to the nasal spray, the label calls for ten times the injected amount; when switching from tablets to the spray, it notes that intranasal desmopressin is roughly 10 to 40 times more potent than the oral tablet⁵. So the three routes line up the way the physiology predicts: injection, then nasal, then oral.

The label also shows what makes nasal dosing tricky. The pump delivers only 10 mcg per spray, so doses that are not multiples of 10 mcg cannot be given with it; the bottle must be primed and discarded after 50 sprays; and long-term use can change the nasal lining — scarring or swelling — which can alter absorption⁵. A home-mixed nasal solution of a research peptide has no characterized spray volume, no stability data, and no evidence on how much crosses the nasal lining.

The best-known nasal research peptides are Semax and Selank. Both were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, and both are among the peptide products registered in the Russian Federation, as a nootropic and an anxiolytic respectively⁷. Semax research describes effects on learning and memory after intranasal application in rodents and humans⁸. Neither is FDA-approved. FDA's compounding safety page lists both with a note that compounded products may pose a risk of immunogenicity and that the agency lacks safety information for them¹⁰. For what the studies actually show, see our comparison of Semax vs Selank.

Topical peptides: GHK-Cu and the skin

Topical peptides are a different category altogether. GHK-Cu, the copper-binding tripeptide, is sold as a cosmetic ingredient in creams and serums. A 2015 review by Loren Pickart — who first described GHK — and colleagues summarizes several placebo-controlled 12-week cosmetic studies in women with photodamaged skin, including a facial cream study of 71 women and an eye cream study of 41 women, reporting improvements in fine lines, laxity and skin density⁹. These are small studies, mostly summarized secondhand, and they measured skin appearance — not blood levels.

The skin evidence says nothing about injecting GHK-Cu. FDA lists 'GHK-Cu (for injectable routes of administration)' separately, noting that compounded injectable GHK-Cu may pose a risk of immunogenicity and that there are limited data in humans to inform safety¹⁰. Same molecule, different route, different evidence base. More detail is on our GHK-Cu reference page.

Injection: subcutaneous or intramuscular

Within injections there is one more choice. Peptides are almost always given subcutaneously — into the fat layer with a short insulin-syringe needle — which is how Vyleesi, semaglutide and tirzepatide pens are labeled. Intramuscular injection is standard for oil-based testosterone esters, not for water-based peptides; the differences are covered in our subcutaneous vs intramuscular guide. If your peptide comes as a powder, the dose you draw depends entirely on how much water you add, and our insulin syringe units guide explains how to convert units to mcg.

Storage basics: follow the form you actually have

Storage depends on the product, and approved products spell it out on the label. The examples below show how much it varies even among peptides:

Freeze-dried powder and reconstituted solution are not the same product. Once water is added, the clock starts, and for research peptides nobody has published how fast that particular vial loses potency. The half-life guide covers the separate question of how long a dose stays active in the body.

Questions to settle before choosing a route

1. Is there an approved product for what you want, and in which form? If there is, its label defines the route, dose, timing and storage — and every other form of the same molecule is off-label.
2. Has the route you're considering been studied in humans for this specific peptide, with blood levels measured? For most research peptides the honest answer is no, whatever the route.
3. Does the dose change with the route? For desmopressin, going from injection to nasal spray is a tenfold change; for semaglutide, two tablet formulations of the same molecule are not interchangeable milligram for milligram (both covered above). Assume the dose changes until data show otherwise.
4. Can you meet the route's practical requirements every day — the fasting window for tablets, sterile technique and refrigeration for injections?
5. Who is supervising? Changing route is a prescribing decision; bring the question to a clinician rather than working it out from forum posts.

This is an explainer, not a prescription

Nothing here is a recommendation to use any peptide by any route. Most compounds discussed on this site are not approved for the uses people search for, and the evidence for them ranges from clinical trials to animal studies only — each compound page marks which tier applies. For a broader look at the risks, read Are peptides safe?

FAQ

References

Primary sources — PubMed / NEJM / The Lancet.

1. Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov. 2020;19(4):277-289. https://pubmed.ncbi.nlm.nih.gov/31848464/
2. U.S. FDA. RYBELSUS and OZEMPIC (semaglutide) tablets, for oral use — Prescribing Information. Novo Nordisk. Revised 1/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf
3. Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047. https://pubmed.ncbi.nlm.nih.gov/30429357/
4. Novo Nordisk. FDA approves Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults. Press release, 22 December 2025. https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html
5. U.S. FDA. DDAVP (desmopressin acetate) nasal spray — Prescribing Information. Ferring Pharmaceuticals. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/017922s046lbl.pdf
6. U.S. FDA. VYLEESI (bremelanotide injection), for subcutaneous use — Prescribing Information. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
7. Deigin VI, Poluektova EA, Beniashvili AG, Kozin SA, Poluektov YM. Development of Peptide Biopharmaceuticals in Russia. Pharmaceutics. 2022;14(4):716. https://pmc.ncbi.nlm.nih.gov/articles/PMC9030433/
8. Dolotov OV, Karpenko EA, Seredenina TS, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97 Suppl 1:82-86. https://pubmed.ncbi.nlm.nih.gov/16635254/
9. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
10. U.S. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of 04/22/2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks